FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer

Coverage, in order

1. 5d ago
   first FDA Drug Safety / Drugs feed indie

   FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer

   On October 8, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon c

2. 5d ago
   FDA Drug Safety / Drugs feed indie

   FDA approves durvalumab with chemotherapy for mismatch repair deficient primary advanced or recurrent endometrial cancer

   On June 14, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca UK Limited) with carboplatin plus paclitaxel followed by single-agent durvalumab for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.